Joaquin Espinosa
Concepts (463)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Down Syndrome | 33 | 2026 | 534 | 8.650 |
Why?
| | Tumor Suppressor Protein p53 | 17 | 2025 | 529 | 4.450 |
Why?
| | Transcription, Genetic | 13 | 2021 | 1496 | 2.000 |
Why?
| | Cyclin-Dependent Kinases | 7 | 2022 | 123 | 1.860 |
Why?
| | Transcriptome | 7 | 2026 | 1045 | 1.850 |
Why?
| | Neoplasms | 12 | 2026 | 2875 | 1.680 |
Why?
| | Transcriptional Activation | 7 | 2023 | 383 | 1.660 |
Why?
| | Proteome | 6 | 2026 | 518 | 1.570 |
Why?
| | Janus Kinase Inhibitors | 2 | 2024 | 28 | 1.520 |
Why?
| | Chromosomes, Human, Pair 21 | 2 | 2024 | 42 | 1.440 |
Why?
| | Piperidines | 2 | 2024 | 217 | 1.370 |
Why?
| | Interferons | 5 | 2026 | 188 | 1.360 |
Why?
| | Pyrimidines | 3 | 2024 | 532 | 1.260 |
Why?
| | Hypoxia | 3 | 2026 | 1199 | 1.030 |
Why?
| | Receptors, Interferon | 3 | 2026 | 60 | 1.020 |
Why?
| | Human Development | 1 | 2025 | 21 | 0.910 |
Why?
| | Genomics | 2 | 2021 | 834 | 0.900 |
Why?
| | Metabolome | 3 | 2026 | 384 | 0.900 |
Why?
| | Antineoplastic Agents | 5 | 2025 | 2194 | 0.880 |
Why?
| | Gene Regulatory Networks | 2 | 2021 | 318 | 0.870 |
Why?
| | Immunoglobulins | 1 | 2025 | 160 | 0.850 |
Why?
| | Erythropoiesis | 1 | 2024 | 57 | 0.840 |
Why?
| | Heme | 1 | 2024 | 89 | 0.810 |
Why?
| | Blood-Brain Barrier | 1 | 2025 | 155 | 0.800 |
Why?
| | Protein Phosphatase 2C | 1 | 2022 | 15 | 0.760 |
Why?
| | Gene Expression Regulation, Neoplastic | 8 | 2021 | 1455 | 0.760 |
Why?
| | Interferon-alpha | 3 | 2020 | 197 | 0.740 |
Why?
| | Cell Death | 2 | 2025 | 383 | 0.720 |
Why?
| | Transcription Factors | 9 | 2023 | 1741 | 0.710 |
Why?
| | Molecular Targeted Therapy | 1 | 2025 | 432 | 0.710 |
Why?
| | Heart Defects, Congenital | 3 | 2026 | 914 | 0.700 |
Why?
| | Blood | 1 | 2022 | 109 | 0.700 |
Why?
| | Arthritis, Psoriatic | 1 | 2021 | 15 | 0.700 |
Why?
| | Humans | 77 | 2026 | 144759 | 0.690 |
Why?
| | Genes, Tumor Suppressor | 1 | 2021 | 83 | 0.660 |
Why?
| | Apoptosis | 11 | 2025 | 2430 | 0.650 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 6 | 2025 | 66 | 0.640 |
Why?
| | Oncogenes | 1 | 2021 | 119 | 0.640 |
Why?
| | Databases, Genetic | 1 | 2021 | 248 | 0.630 |
Why?
| | Kynurenine | 2 | 2023 | 114 | 0.620 |
Why?
| | Sex Characteristics | 1 | 2025 | 790 | 0.620 |
Why?
| | Trisomy | 2 | 2019 | 78 | 0.600 |
Why?
| | Signal Transduction | 9 | 2024 | 5226 | 0.580 |
Why?
| | Tumor Suppressor Proteins | 2 | 2018 | 321 | 0.570 |
Why?
| | Enhancer Elements, Genetic | 1 | 2020 | 192 | 0.560 |
Why?
| | Cyclin-Dependent Kinase 8 | 6 | 2022 | 50 | 0.560 |
Why?
| | Autoimmunity | 2 | 2023 | 926 | 0.530 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 415 | 0.520 |
Why?
| | Animals | 31 | 2026 | 38058 | 0.520 |
Why?
| | Case-Control Studies | 7 | 2025 | 3604 | 0.510 |
Why?
| | CD57 Antigens | 1 | 2016 | 18 | 0.480 |
Why?
| | Abatacept | 1 | 2016 | 56 | 0.470 |
Why?
| | Cell Proliferation | 7 | 2025 | 2496 | 0.460 |
Why?
| | Adult | 20 | 2026 | 40449 | 0.440 |
Why?
| | Mice | 18 | 2026 | 18339 | 0.420 |
Why?
| | Interferon-gamma | 3 | 2026 | 784 | 0.420 |
Why?
| | Female | 33 | 2026 | 78271 | 0.410 |
Why?
| | Cell Line, Tumor | 9 | 2023 | 3540 | 0.410 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2018 | 641 | 0.390 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2024 | 297 | 0.390 |
Why?
| | Proteomics | 4 | 2025 | 1195 | 0.390 |
Why?
| | Cyclins | 3 | 2022 | 84 | 0.370 |
Why?
| | Gene Expression Profiling | 5 | 2024 | 1782 | 0.370 |
Why?
| | Graft Rejection | 1 | 2016 | 540 | 0.370 |
Why?
| | Male | 25 | 2026 | 72315 | 0.370 |
Why?
| | Young Adult | 10 | 2026 | 14105 | 0.360 |
Why?
| | Datasets as Topic | 2 | 2022 | 122 | 0.340 |
Why?
| | Adolescent | 11 | 2026 | 22428 | 0.340 |
Why?
| | Immunosuppressive Agents | 1 | 2016 | 846 | 0.330 |
Why?
| | Alzheimer Disease | 3 | 2025 | 621 | 0.330 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2023 | 1129 | 0.330 |
Why?
| | Cell Cycle Proteins | 4 | 2023 | 628 | 0.320 |
Why?
| | Cell Differentiation | 3 | 2024 | 2050 | 0.320 |
Why?
| | Triple Negative Breast Neoplasms | 3 | 2019 | 215 | 0.320 |
Why?
| | RNA Polymerase II | 4 | 2019 | 351 | 0.320 |
Why?
| | Cell Line | 5 | 2021 | 2882 | 0.300 |
Why?
| | Child, Preschool | 8 | 2026 | 11787 | 0.300 |
Why?
| | Kidney Transplantation | 1 | 2016 | 704 | 0.300 |
Why?
| | Biomarkers | 5 | 2025 | 4271 | 0.290 |
Why?
| | Mediator Complex | 3 | 2022 | 61 | 0.290 |
Why?
| | Early Detection of Cancer | 2 | 2026 | 463 | 0.270 |
Why?
| | DNA-Binding Proteins | 4 | 2016 | 1499 | 0.260 |
Why?
| | Proto-Oncogene Proteins | 2 | 2023 | 623 | 0.260 |
Why?
| | Child | 11 | 2026 | 22633 | 0.260 |
Why?
| | Promoter Regions, Genetic | 4 | 2013 | 1257 | 0.250 |
Why?
| | Gene Expression Regulation | 3 | 2012 | 2608 | 0.250 |
Why?
| | Trypanosoma cruzi | 4 | 2000 | 39 | 0.250 |
Why?
| | Flow Cytometry | 3 | 2019 | 1173 | 0.250 |
Why?
| | Cytokines | 5 | 2024 | 2061 | 0.250 |
Why?
| | Disease Models, Animal | 7 | 2026 | 4557 | 0.250 |
Why?
| | Phenotype | 2 | 2026 | 3162 | 0.240 |
Why?
| | Candidiasis, Oral | 1 | 2026 | 19 | 0.240 |
Why?
| | Middle Aged | 13 | 2026 | 35875 | 0.240 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2006 | 29 | 0.240 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2009 | 112 | 0.230 |
Why?
| | Cell Cycle | 2 | 2008 | 596 | 0.230 |
Why?
| | Platelet Activation | 1 | 2026 | 104 | 0.230 |
Why?
| | Phosphorylation | 4 | 2022 | 1732 | 0.230 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2637 | 0.220 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2025 | 161 | 0.220 |
Why?
| | Metabolomics | 2 | 2021 | 727 | 0.220 |
Why?
| | Heart | 2 | 2025 | 636 | 0.210 |
Why?
| | Mechanotransduction, Cellular | 1 | 2025 | 122 | 0.210 |
Why?
| | Polymerase Chain Reaction | 2 | 2019 | 1054 | 0.210 |
Why?
| | Protein Binding | 5 | 2021 | 2273 | 0.210 |
Why?
| | Hemoglobin SC Disease | 1 | 2023 | 14 | 0.200 |
Why?
| | Erythropoietin | 1 | 2024 | 100 | 0.200 |
Why?
| | Homeodomain Proteins | 2 | 2019 | 523 | 0.200 |
Why?
| | Oxidative Phosphorylation | 1 | 2024 | 210 | 0.200 |
Why?
| | Liposarcoma | 1 | 2023 | 31 | 0.200 |
Why?
| | Glutamine | 1 | 2023 | 109 | 0.190 |
Why?
| | Hypertension, Pulmonary | 2 | 2026 | 1980 | 0.190 |
Why?
| | Cyclin C | 1 | 2022 | 2 | 0.190 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2022 | 33 | 0.190 |
Why?
| | Growth Disorders | 1 | 2022 | 86 | 0.180 |
Why?
| | Diabetic Neuropathies | 1 | 2023 | 99 | 0.180 |
Why?
| | Centrosome | 2 | 2022 | 71 | 0.180 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2022 | 73 | 0.180 |
Why?
| | Nuclear Proteins | 4 | 2023 | 748 | 0.180 |
Why?
| | Gene Silencing | 1 | 2023 | 205 | 0.180 |
Why?
| | Nervous System Diseases | 1 | 2025 | 284 | 0.180 |
Why?
| | Acetyltransferases | 1 | 2001 | 21 | 0.170 |
Why?
| | Cerebellar Neoplasms | 1 | 2023 | 177 | 0.170 |
Why?
| | Up-Regulation | 3 | 2021 | 851 | 0.170 |
Why?
| | Medulloblastoma | 1 | 2023 | 215 | 0.170 |
Why?
| | Access to Information | 1 | 2021 | 48 | 0.170 |
Why?
| | Stress, Physiological | 1 | 2024 | 453 | 0.170 |
Why?
| | Hematopoiesis | 2 | 2021 | 194 | 0.170 |
Why?
| | Cilia | 2 | 2022 | 173 | 0.170 |
Why?
| | Janus Kinase 2 | 1 | 2020 | 29 | 0.170 |
Why?
| | Janus Kinase 1 | 1 | 2020 | 26 | 0.170 |
Why?
| | Azetidines | 1 | 2020 | 45 | 0.160 |
Why?
| | RNA, Messenger | 4 | 2021 | 2832 | 0.160 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 319 | 0.160 |
Why?
| | MicroRNAs | 2 | 2018 | 701 | 0.160 |
Why?
| | Data Mining | 1 | 2021 | 117 | 0.160 |
Why?
| | Doxorubicin | 3 | 2007 | 397 | 0.160 |
Why?
| | Models, Biological | 1 | 2008 | 1821 | 0.160 |
Why?
| | Eosinophilic Esophagitis | 1 | 2024 | 330 | 0.160 |
Why?
| | Autoantigens | 1 | 2023 | 429 | 0.160 |
Why?
| | Quinolinic Acid | 1 | 2019 | 7 | 0.160 |
Why?
| | Connective Tissue Diseases | 1 | 2020 | 84 | 0.150 |
Why?
| | Heart Diseases | 1 | 2023 | 349 | 0.150 |
Why?
| | Biosynthetic Pathways | 1 | 2019 | 25 | 0.150 |
Why?
| | DNA, Protozoan | 1 | 1999 | 32 | 0.150 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 55 | 0.150 |
Why?
| | Anemia, Sickle Cell | 1 | 2023 | 312 | 0.150 |
Why?
| | Liver | 2 | 2026 | 1887 | 0.150 |
Why?
| | Transcription Factor AP-1 | 1 | 1999 | 79 | 0.150 |
Why?
| | Preimplantation Diagnosis | 1 | 2019 | 6 | 0.150 |
Why?
| | Sex Determination Analysis | 1 | 2019 | 9 | 0.150 |
Why?
| | Blastocyst | 1 | 2019 | 47 | 0.140 |
Why?
| | Neurons | 2 | 2025 | 1640 | 0.140 |
Why?
| | Protozoan Proteins | 1 | 1999 | 93 | 0.140 |
Why?
| | Cognitive Dysfunction | 1 | 2025 | 461 | 0.140 |
Why?
| | Protein Domains | 2 | 2017 | 313 | 0.140 |
Why?
| | Occult Blood | 1 | 2018 | 40 | 0.140 |
Why?
| | Tibia | 1 | 2020 | 176 | 0.140 |
Why?
| | Calcinosis | 1 | 2020 | 234 | 0.140 |
Why?
| | Cell Survival | 2 | 2021 | 1098 | 0.140 |
Why?
| | Genome, Human | 1 | 2021 | 422 | 0.140 |
Why?
| | Coinfection | 1 | 2020 | 141 | 0.140 |
Why?
| | Nedd4 Ubiquitin Protein Ligases | 1 | 2018 | 15 | 0.140 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2018 | 33 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2019 | 67 | 0.140 |
Why?
| | Forkhead Box Protein O3 | 1 | 2018 | 18 | 0.140 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2018 | 76 | 0.140 |
Why?
| | Mice, Inbred C57BL | 5 | 2020 | 5992 | 0.140 |
Why?
| | Kidney Function Tests | 2 | 2016 | 157 | 0.140 |
Why?
| | Embryo, Mammalian | 1 | 2019 | 232 | 0.140 |
Why?
| | Stem Cell Niche | 1 | 2018 | 58 | 0.140 |
Why?
| | Bacterial Infections | 1 | 2020 | 246 | 0.140 |
Why?
| | Epithelial Cells | 1 | 2024 | 1125 | 0.140 |
Why?
| | Receptor, Notch1 | 1 | 2018 | 64 | 0.130 |
Why?
| | Horses | 1 | 2019 | 201 | 0.130 |
Why?
| | Cell Lineage | 1 | 2019 | 376 | 0.130 |
Why?
| | Hypersensitivity | 1 | 2020 | 252 | 0.130 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2021 | 449 | 0.130 |
Why?
| | Reminder Systems | 1 | 2018 | 141 | 0.130 |
Why?
| | Inpatients | 1 | 2022 | 545 | 0.130 |
Why?
| | Inflammation | 2 | 2020 | 2878 | 0.130 |
Why?
| | Binding Sites | 3 | 2014 | 1329 | 0.130 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2023 | 917 | 0.130 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 186 | 0.130 |
Why?
| | Cellular Senescence | 1 | 2019 | 226 | 0.130 |
Why?
| | Leukemia, Biphenotypic, Acute | 1 | 2017 | 4 | 0.130 |
Why?
| | Hedgehog Proteins | 1 | 2018 | 197 | 0.130 |
Why?
| | Prospective Studies | 3 | 2025 | 7990 | 0.130 |
Why?
| | Proteins | 1 | 2023 | 1021 | 0.120 |
Why?
| | Febrile Neutropenia | 1 | 2016 | 6 | 0.120 |
Why?
| | Cohort Studies | 2 | 2026 | 5960 | 0.120 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2019 | 389 | 0.120 |
Why?
| | T-Lymphocytes | 2 | 2022 | 1982 | 0.120 |
Why?
| | Osteoarthritis, Knee | 1 | 2020 | 279 | 0.120 |
Why?
| | Osteosarcoma | 1 | 2017 | 76 | 0.120 |
Why?
| | Histidine Kinase | 1 | 2016 | 34 | 0.120 |
Why?
| | Sulfonamides | 1 | 2020 | 580 | 0.120 |
Why?
| | Antigens | 1 | 2018 | 347 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 2 | 2020 | 969 | 0.120 |
Why?
| | Exosomes | 1 | 2017 | 104 | 0.120 |
Why?
| | Proteolysis | 1 | 2017 | 173 | 0.120 |
Why?
| | Chromatin | 4 | 2016 | 561 | 0.120 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 1126 | 0.120 |
Why?
| | HCT116 Cells | 3 | 2019 | 78 | 0.120 |
Why?
| | Adenosine Triphosphatases | 1 | 2016 | 162 | 0.120 |
Why?
| | Colonic Neoplasms | 1 | 2018 | 259 | 0.110 |
Why?
| | Follow-Up Studies | 4 | 2020 | 5408 | 0.110 |
Why?
| | Neurofilament Proteins | 3 | 2025 | 78 | 0.110 |
Why?
| | Autophagy | 1 | 2018 | 286 | 0.110 |
Why?
| | Ribosomal Proteins | 1 | 2015 | 91 | 0.110 |
Why?
| | Drug Resistance | 1 | 2016 | 153 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2019 | 1137 | 0.110 |
Why?
| | Allografts | 1 | 2016 | 150 | 0.110 |
Why?
| | Patient Participation | 1 | 2018 | 431 | 0.110 |
Why?
| | Hematopoietic Stem Cells | 1 | 2018 | 420 | 0.110 |
Why?
| | Nerve Tissue Proteins | 1 | 2019 | 592 | 0.110 |
Why?
| | Aging | 1 | 2025 | 1966 | 0.110 |
Why?
| | Bone Neoplasms | 1 | 2017 | 253 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 412 | 0.110 |
Why?
| | Gene Expression | 1 | 2019 | 1490 | 0.110 |
Why?
| | Azepines | 1 | 2015 | 107 | 0.110 |
Why?
| | Infant | 3 | 2025 | 10034 | 0.100 |
Why?
| | Carrier Proteins | 1 | 2018 | 737 | 0.100 |
Why?
| | Repressor Proteins | 1 | 2017 | 437 | 0.100 |
Why?
| | Acetylation | 2 | 2007 | 252 | 0.100 |
Why?
| | ets-Domain Protein Elk-1 | 1 | 2013 | 11 | 0.100 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2016 | 758 | 0.100 |
Why?
| | Fibroblasts | 1 | 2019 | 1034 | 0.100 |
Why?
| | Mitogens | 1 | 2013 | 55 | 0.100 |
Why?
| | Bile Acids and Salts | 2 | 2026 | 164 | 0.100 |
Why?
| | Prognosis | 3 | 2019 | 4282 | 0.100 |
Why?
| | Immunologic Memory | 1 | 2016 | 366 | 0.100 |
Why?
| | Down-Regulation | 1 | 2015 | 627 | 0.100 |
Why?
| | Graft Survival | 1 | 2016 | 526 | 0.100 |
Why?
| | Disease Progression | 1 | 2021 | 2847 | 0.100 |
Why?
| | Immunohistochemistry | 2 | 2016 | 1716 | 0.100 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 173 | 0.090 |
Why?
| | Amphotericin B | 1 | 2012 | 37 | 0.090 |
Why?
| | Feedback, Physiological | 1 | 2012 | 83 | 0.090 |
Why?
| | Obesity | 1 | 2026 | 3077 | 0.090 |
Why?
| | Spain | 2 | 2025 | 48 | 0.090 |
Why?
| | Tumor Cells, Cultured | 3 | 2019 | 919 | 0.090 |
Why?
| | Glomerular Filtration Rate | 1 | 2016 | 760 | 0.090 |
Why?
| | RNA Stability | 1 | 2012 | 119 | 0.090 |
Why?
| | Antifungal Agents | 1 | 2012 | 149 | 0.090 |
Why?
| | Protein Structure, Tertiary | 2 | 2006 | 862 | 0.090 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 845 | 0.080 |
Why?
| | Risk Factors | 3 | 2025 | 10779 | 0.080 |
Why?
| | Mass Screening | 1 | 2018 | 1347 | 0.080 |
Why?
| | Kidney Failure, Chronic | 1 | 2016 | 598 | 0.080 |
Why?
| | HeLa Cells | 3 | 2013 | 650 | 0.080 |
Why?
| | Sirtuins | 1 | 2010 | 50 | 0.080 |
Why?
| | Imidazoles | 2 | 2023 | 254 | 0.070 |
Why?
| | Enzyme Activation | 2 | 2008 | 766 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2023 | 459 | 0.070 |
Why?
| | S Phase | 1 | 2009 | 80 | 0.070 |
Why?
| | Protamine Kinase | 1 | 2008 | 8 | 0.070 |
Why?
| | Receptors, Thyroid Hormone | 1 | 2008 | 18 | 0.070 |
Why?
| | Histones | 2 | 2007 | 669 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2583 | 0.070 |
Why?
| | Hydroxyurea | 2 | 2023 | 34 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2012 | 427 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2925 | 0.070 |
Why?
| | Piperazines | 2 | 2023 | 381 | 0.070 |
Why?
| | Glial Fibrillary Acidic Protein | 2 | 2025 | 124 | 0.070 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2007 | 47 | 0.070 |
Why?
| | Multiprotein Complexes | 1 | 2008 | 172 | 0.070 |
Why?
| | RNA | 1 | 2014 | 940 | 0.060 |
Why?
| | Protein Kinases | 1 | 2009 | 315 | 0.060 |
Why?
| | Formaldehyde | 1 | 2007 | 66 | 0.060 |
Why?
| | Genome-Wide Association Study | 2 | 2025 | 1406 | 0.060 |
Why?
| | Radiation, Ionizing | 1 | 2007 | 87 | 0.060 |
Why?
| | Glycolysis | 2 | 2024 | 339 | 0.060 |
Why?
| | RNA Precursors | 1 | 2007 | 156 | 0.060 |
Why?
| | Fluorouracil | 1 | 2007 | 235 | 0.060 |
Why?
| | DNA | 2 | 2006 | 1463 | 0.060 |
Why?
| | Endocardial Cushions | 1 | 2025 | 7 | 0.060 |
Why?
| | Kinetics | 2 | 2007 | 1627 | 0.060 |
Why?
| | High Mobility Group Proteins | 1 | 2006 | 45 | 0.060 |
Why?
| | Transcription Factors, TFII | 1 | 2006 | 44 | 0.060 |
Why?
| | Transcriptional Elongation Factors | 1 | 2006 | 39 | 0.060 |
Why?
| | Critical Illness | 1 | 2012 | 891 | 0.060 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2006 | 139 | 0.060 |
Why?
| | Candida albicans | 1 | 2026 | 61 | 0.060 |
Why?
| | Transcription Factor TFIIH | 1 | 2006 | 40 | 0.060 |
Why?
| | Protein Transport | 1 | 2007 | 441 | 0.060 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2025 | 68 | 0.060 |
Why?
| | Serine | 1 | 2006 | 145 | 0.060 |
Why?
| | SEER Program | 1 | 2026 | 224 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2019 | 3121 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2018 | 2452 | 0.060 |
Why?
| | Myocytes, Cardiac | 2 | 2025 | 556 | 0.050 |
Why?
| | Kidney | 1 | 2012 | 1495 | 0.050 |
Why?
| | Glucose | 1 | 2010 | 1047 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2006 | 402 | 0.050 |
Why?
| | Aged | 6 | 2025 | 25913 | 0.050 |
Why?
| | Vascular Remodeling | 1 | 2026 | 205 | 0.050 |
Why?
| | Disease Susceptibility | 1 | 2026 | 348 | 0.050 |
Why?
| | Hemoglobin, Sickle | 1 | 2023 | 19 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 983 | 0.050 |
Why?
| | Headache | 1 | 2025 | 150 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2019 | 928 | 0.050 |
Why?
| | Intermediate Filaments | 1 | 2023 | 25 | 0.050 |
Why?
| | Glutamates | 1 | 2023 | 66 | 0.050 |
Why?
| | Activating Transcription Factor 4 | 1 | 2023 | 22 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2023 | 40 | 0.050 |
Why?
| | L-Selectin | 1 | 2023 | 27 | 0.050 |
Why?
| | Perforin | 1 | 2023 | 21 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2026 | 17066 | 0.050 |
Why?
| | Proline | 1 | 2023 | 83 | 0.050 |
Why?
| | Tyrosine | 1 | 2023 | 222 | 0.050 |
Why?
| | Patient Acuity | 1 | 2023 | 47 | 0.050 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2025 | 276 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8265 | 0.050 |
Why?
| | Blood Platelets | 1 | 2026 | 400 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2023 | 167 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2023 | 159 | 0.050 |
Why?
| | Esophagus | 1 | 2024 | 261 | 0.050 |
Why?
| | Cells, Cultured | 3 | 2018 | 4154 | 0.040 |
Why?
| | Hemolysis | 1 | 2023 | 243 | 0.040 |
Why?
| | Centrioles | 1 | 2022 | 47 | 0.040 |
Why?
| | DNA Footprinting | 1 | 2001 | 33 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2022 | 156 | 0.040 |
Why?
| | Neuroimaging | 1 | 2024 | 289 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2025 | 553 | 0.040 |
Why?
| | p300-CBP Transcription Factors | 1 | 2001 | 26 | 0.040 |
Why?
| | Nitric Oxide | 2 | 1997 | 897 | 0.040 |
Why?
| | Nerve Regeneration | 1 | 2001 | 56 | 0.040 |
Why?
| | Genes, Protozoan | 1 | 2000 | 13 | 0.040 |
Why?
| | Immunoblotting | 1 | 2001 | 300 | 0.040 |
Why?
| | Histone Acetyltransferases | 1 | 2001 | 62 | 0.040 |
Why?
| | Clonal Evolution | 1 | 2021 | 47 | 0.040 |
Why?
| | RNA Helicases | 1 | 2000 | 31 | 0.040 |
Why?
| | Antigens, Neoplasm | 1 | 2022 | 271 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2025 | 1134 | 0.040 |
Why?
| | Oligonucleotide Probes | 1 | 1999 | 50 | 0.040 |
Why?
| | Electrophoresis | 1 | 1999 | 31 | 0.040 |
Why?
| | Heterozygote | 1 | 2020 | 315 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2020 | 172 | 0.040 |
Why?
| | Vesiculovirus | 1 | 2019 | 17 | 0.040 |
Why?
| | Genetic Testing | 1 | 2022 | 478 | 0.040 |
Why?
| | Interferon Type I | 1 | 2020 | 145 | 0.040 |
Why?
| | Purines | 1 | 2020 | 187 | 0.040 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 194 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 1999 | 55 | 0.040 |
Why?
| | Microtubules | 1 | 2022 | 286 | 0.040 |
Why?
| | STAT1 Transcription Factor | 1 | 2019 | 68 | 0.040 |
Why?
| | Drosophila melanogaster | 1 | 2001 | 236 | 0.040 |
Why?
| | Veterinary Sports Medicine | 1 | 2019 | 1 | 0.040 |
Why?
| | Nanog Homeobox Protein | 1 | 2019 | 14 | 0.040 |
Why?
| | Argentina | 1 | 2019 | 30 | 0.040 |
Why?
| | Osteotomy | 1 | 2020 | 127 | 0.040 |
Why?
| | Immunotherapy | 1 | 2024 | 653 | 0.040 |
Why?
| | Postal Service | 1 | 2018 | 27 | 0.040 |
Why?
| | Prevalence | 1 | 2026 | 2834 | 0.040 |
Why?
| | Biopsy | 2 | 2019 | 1075 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 337 | 0.040 |
Why?
| | Breeding | 1 | 2019 | 63 | 0.040 |
Why?
| | Embryo Transfer | 1 | 2019 | 37 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1999 | 196 | 0.040 |
Why?
| | Myelopoiesis | 1 | 2018 | 10 | 0.040 |
Why?
| | Lymphopoiesis | 1 | 2018 | 27 | 0.040 |
Why?
| | DNA, Single-Stranded | 1 | 1999 | 119 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2001 | 675 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2018 | 86 | 0.030 |
Why?
| | Arginine | 2 | 1997 | 262 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2026 | 1560 | 0.030 |
Why?
| | Commerce | 1 | 2019 | 79 | 0.030 |
Why?
| | Mice, SCID | 1 | 2019 | 369 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2018 | 135 | 0.030 |
Why?
| | Receptors, Growth Factor | 1 | 2017 | 56 | 0.030 |
Why?
| | Amyloid beta-Peptides | 1 | 2020 | 241 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2025 | 2145 | 0.030 |
Why?
| | omega-N-Methylarginine | 1 | 1997 | 29 | 0.030 |
Why?
| | Antibodies | 1 | 1999 | 401 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2947 | 0.030 |
Why?
| | Ubiquitin-Conjugating Enzymes | 1 | 2017 | 17 | 0.030 |
Why?
| | Rats | 1 | 2025 | 5597 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 610 | 0.030 |
Why?
| | Blotting, Western | 1 | 1999 | 1187 | 0.030 |
Why?
| | Pyrazoles | 1 | 2020 | 509 | 0.030 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2017 | 40 | 0.030 |
Why?
| | Epilepsy | 1 | 2001 | 376 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2025 | 2363 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 371 | 0.030 |
Why?
| | Knee Joint | 1 | 2020 | 426 | 0.030 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2017 | 72 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2019 | 688 | 0.030 |
Why?
| | Mitosis | 1 | 2017 | 200 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1253 | 0.030 |
Why?
| | Tumor Protein p73 | 1 | 2015 | 18 | 0.030 |
Why?
| | Cholesterol | 1 | 2017 | 406 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2018 | 457 | 0.030 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2017 | 141 | 0.030 |
Why?
| | Aurora Kinase A | 1 | 2015 | 62 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2020 | 846 | 0.030 |
Why?
| | Hospitalization | 1 | 2025 | 2433 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2017 | 316 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2089 | 0.030 |
Why?
| | Genes, Immediate-Early | 1 | 2013 | 26 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 965 | 0.030 |
Why?
| | Genes, ras | 1 | 2013 | 96 | 0.020 |
Why?
| | Protein Conformation | 1 | 2016 | 946 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2013 | 148 | 0.020 |
Why?
| | Interleukin-1 | 1 | 2017 | 961 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2018 | 876 | 0.020 |
Why?
| | Lung | 1 | 2026 | 4109 | 0.020 |
Why?
| | Oxidative Stress | 1 | 1999 | 1339 | 0.020 |
Why?
| | Mycoses | 1 | 2012 | 88 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1313 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1813 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2013 | 744 | 0.020 |
Why?
| | Creatinine | 1 | 2012 | 506 | 0.020 |
Why?
| | Glucose Transporter Type 1 | 1 | 2010 | 48 | 0.020 |
Why?
| | Cell Respiration | 1 | 2010 | 107 | 0.020 |
Why?
| | Daunorubicin | 1 | 2009 | 25 | 0.020 |
Why?
| | Nucleic Acid Synthesis Inhibitors | 1 | 2009 | 16 | 0.020 |
Why?
| | Checkpoint Kinase 2 | 1 | 2009 | 27 | 0.020 |
Why?
| | Checkpoint Kinase 1 | 1 | 2009 | 27 | 0.020 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2009 | 69 | 0.020 |
Why?
| | Coenzymes | 1 | 2008 | 19 | 0.020 |
Why?
| | Caffeine | 1 | 2009 | 74 | 0.020 |
Why?
| | Brain | 1 | 2001 | 2933 | 0.020 |
Why?
| | United States | 1 | 2026 | 15966 | 0.020 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 11 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2008 | 388 | 0.020 |
Why?
| | RNA Caps | 1 | 2007 | 33 | 0.020 |
Why?
| | Genes, myc | 1 | 2007 | 50 | 0.020 |
Why?
| | Poly A | 1 | 2007 | 50 | 0.020 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2007 | 26 | 0.020 |
Why?
| | DNA Replication | 1 | 2009 | 251 | 0.020 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 269 | 0.020 |
Why?
| | Dizocilpine Maleate | 2 | 1997 | 24 | 0.020 |
Why?
| | Cyclic GMP | 2 | 1997 | 92 | 0.010 |
Why?
| | Pregnancy | 1 | 2019 | 7190 | 0.010 |
Why?
| | Nitric Oxide Synthase | 2 | 1997 | 235 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2008 | 1370 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 2008 | 750 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2020 | 11679 | 0.010 |
Why?
| | Mutation | 1 | 2013 | 4089 | 0.010 |
Why?
| | Models, Molecular | 1 | 2007 | 1618 | 0.010 |
Why?
| | Genomic Library | 1 | 2000 | 17 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2001 | 415 | 0.010 |
Why?
| | RNA, Protozoan | 1 | 2000 | 60 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 276 | 0.010 |
Why?
| | Amino Acid Motifs | 1 | 2000 | 224 | 0.010 |
Why?
| | tau Proteins | 1 | 2001 | 115 | 0.010 |
Why?
| | Microtubule-Associated Proteins | 1 | 2001 | 196 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2000 | 510 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2001 | 375 | 0.010 |
Why?
| | Bucladesine | 1 | 1997 | 19 | 0.010 |
Why?
| | Guanosine Monophosphate | 1 | 1997 | 8 | 0.010 |
Why?
| | Guanosine Diphosphate | 1 | 1997 | 20 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2000 | 2155 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2000 | 2930 | 0.010 |
Why?
| | Amino Acid Oxidoreductases | 1 | 1995 | 19 | 0.010 |
Why?
| | Guanylate Cyclase | 1 | 1995 | 39 | 0.010 |
Why?
| | Citrulline | 1 | 1995 | 46 | 0.010 |
Why?
| | Glutamic Acid | 1 | 1997 | 251 | 0.010 |
Why?
| | Movement | 1 | 1997 | 293 | 0.010 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 1995 | 226 | 0.010 |
Why?
| | Amino Acids | 1 | 1997 | 521 | 0.010 |
Why?
| | Brain Neoplasms | 1 | 2001 | 1318 | 0.010 |
Why?
|
|
Espinosa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|